Pharmacokinetics of penicillin G in infants with a gestational age of less than 32 weeks

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 10, 2007, Pages 3720-3725

  Muller, Anouk E ^a   DeJongh, Joost ^b,c   Bult, Ymka ^d,h   Goessens, Wil H F ^e   Mouton, Johan W ^f   Danhof, Meindert ^b,c   Van Den Anker, John N ^d,g  

^a MEDICAL CENTER HAAGLANDEN   (Netherlands)

^b LAP and P Consultants BV   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

^d SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^g CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^h Wilhelmina Ziekenhuis   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PENICILLIN G;

ARTICLE; BIRTH WEIGHT; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; GESTATIONAL AGE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NEWBORN; PREMATURITY; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BODY WEIGHT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GESTATIONAL AGE; HALF-LIFE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; PENICILLIN G; POPULATION; SEPSIS; SEX CHARACTERISTICS; STOCHASTIC PROCESSES;

EID: 34948861093     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00318-07     Document Type: Article

References (32)

1. Adams-Chapman, I., and B. J. Stoll. 2006. Neonatal infection and long-term neurodevelopmental outcome in the preterm infant. Curr. Opin. Infect. Dis. 19:290-297.
2. Adrianzen Vargas, M. R., M. H. Danton, S. M. Javaid, J. Gray, C. Tobin, W. J. Brawn, and D. J. Barron. 2004. Pharmacokinetics of intravenous flucloxacillin and amoxicillin in neonatal and infant cardiopulmonary bypass surgery. Eur. J. Cardiothorac. Surg. 25:256-260.
3. Ambrose, P. G., and D. M. Grasela. 2000. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 38:151-157.
4. Anderson, B. J., K. Allegaert, and N. H. Holford. 2006. Population clinical pharmacology of children: modelling covariate effects. Eur. J. Pediatr. 165:819-829.
5. Benjamin, D. K., Jr., and B. J. Stoll. 2006. Infection in late preterm infants. Clin. Perinatol. 33:871-882.
6. Besunder, J. B., M. D. Reed, and J. L. Blumer. 1988. Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (part I). Clin. Pharmacokinet. 14:189-216.
7. Charles, B. G., Y. Preechagoon, T. C. Lee, P. A. Steer, V. J. Flenady, and N. Debuse. 1997. Population pharmacokinetics of intravenous amoxicillin in very low birth weight infants. J. Pharm. Sci. 86:1288-1292.
8. Craig, W. A. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. N. Am. 17:479-501.
9. Craig, W. A. 1995. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22:89-96.
10. Dahl, L. B., K. Melby, T. J. Gutteberg, and G. Storvold. 1986. Serum levels of ampicillin and gentamycin in neonates of varying gestational age. Eur. J. Pediatr. 145:218-221.
11. de Hoog, M., J. W. Mouton, and J. N. van den Anker. 2005. New dosing strategies for antibacterial agents in the neonate. Semin. Fetal Neonatal Med. 10:185-194.
12. Drusano, G. L., D. Z. D'Argenio, S. L. Preston, C. Barone, W. Symonds, S. LaFon, M. Rogers, W. Prince, A. Bye, and J. A. Bilello. 2000. Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir. Antimicrob. Agents Chemother. 44:1655-1659.
13. Drusano, G. L., S. L. Preston, C. Hardalo, R. Hare, C. Banfield, D. Andes, O. Vesga, and W. A. Craig. 2001. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45:13-22.
14. Ebert, S. C., J. Leggett, B. Vogelman, and W. A. Craig. 1988. Evidence for a slow elimination phase for penicillin G. J. Infect. Dis. 158:200-202.
15. Gabrielsson, J., and D. Weimer. 2000. Pharmacokinetic concepts. In Pharmacokinetic and pharmacodynamic data analysis: concepts & applications, 3rd ed. Apothekarsocieteten, Swedish Pharmaceutical Society, Stockholm, Sweden.
16. Huisman-de Boer, J. J., J. N. van den Anker, M. Vogel, W. H. Goessens, R. C. Schoemaker, and R. de Groot. 1995. Amoxicillin pharmacokinetics in preterm infants with gestational ages of less than 32 weeks. Antimicrob. Agents Chemother. 39:431-434.
17. Kearns, G. L., S. M. Abdel-Rahman, S. W. Alander, D. L. Blowey, J. S. Leeder, and R. E. Kauffman. 2003. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349:1157-1167.
18. Leggett, J. E., B. Fantin, S. Ebert, K. Totsuka, B. Vogelman, W. Calame, H. Mattie, and W. A. Craig. 1989. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J. Infect. Dis. 159:281-292.
19. McCracken, G. H., Jr., C. Ginsberg, D. F. Chrane, M. L. Thomas, and L. J. Horton. 1973. Clinical pharmacology of penicillin in newborn infants. J. Pediatr. 82:692-698.
20. McCracken, G. H., and J. D. Nelson. 1983. Antimicrobial therapy for newborns. Grune & Stratton, New York, NY.
21. Mouton, J. W. 2002. Breakpoints: current practice and future perspectives. Int. J. Antimicrob. Agents 19:323-331.
22. Mouton, J. W., N. Punt, and A. A. Vinks. 2005. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. Clin. Ther. 27:762-772.
23. Mouton, J. W., A. Schmitt-Hoffmann, S. Shapiro, N. Nashed, and N. C. Punt. 2004. Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob. Agents Chemother. 48:1713-1718.
24. Mtitimila, E. I., and R. W. Cooke. 2004. Antibiotic regimens for suspected early neonatal sepsis. Cochrane Database Syst. Rev. CD004495.
25. Mulhall, A. 1985. Antibiotic treatment of neonates - does route of administration matter? Dev. Pharmacol. Ther. 8:1-8.
26. Paap, C. M., and M. C. Nahata. 1990. Clinical pharmacokinetics of antibacterial drugs in neonates. Clin. Pharmacokinet. 19:280-318.
27. Rakhmanina, N. Y., and J. N. van den Anker. 2006. Pharmacological research in pediatrics: from neonates to adolescents. Adv. Drug Deliv. Rev. 58:4-14.
28. Stoll, B. J., N. I. Hansen, R. D. Higgins, A. A. Fanaroff, S. Duara, R. Goldberg, A. Laptook, M. Walsh, W. Oh, and E. Hale. 2005. Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002-2003. Pediatr. Infect. Dis. J. 24:635-639.
29. Tauber, M. G., O. Zak, W. M. Scheid, B. Hengstler, and M. A. Sande. 1984. The postantibiotic effect in the treatment of experimental meningitis caused by Streptococcus pneumoniae in rabbits. J. Infect. Dis. 149:575-583.
30. Vogelman, B., S. Gudmundsson, J. Leggett, J. Tumidge, S. Ebert, and W. A. Craig. 1988. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis. 158:831-847.
31. Yaffe, S. J. 1981. Antimicrobial therapy and the neonate. Obstet. Gynecol. 58:85S-94S.
32. Yoshioka, H., M. Takimoto, and H. D. Riley, Jr. 1974. Pharmacokinetics of ampicillin in the newborn infant. J. Infect. Dis. 129:461-464.